contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biostock-publishes-an-article-after-prolight-published-its-year-end-report-for-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Yesterday, an article was published with the headline “Prolight finalises instrument design and prepare for pilot manufacturing”. However, the article rather describes that the instrument is still being finalized, consistent with previous press releases.                   placera.se              Prolight slutför instrumentdesign och förbereder för pilottillverkning |...    Prolight slutför instrumentdesign och förbereder för pilottillverkning

And then for a slightly more up-to-date situational analysis: the company has turned out to be a disappointment in my case. Schedules are slipping and there is still no information about the clinical trial. I would estimate that new share issues will be arranged by May at the latest, before the summer holidays. Unless a licensing agreement comes as a surprise before then. According to the investor letter published yesterday, the “design freeze” for the device is still not completed and improvements are being worked on. However, for the assay unit itself and its reagents, this was achieved in December.

NOTE: This post has been sitting in draft mode since August, and I only noticed it now. Some time has passed, so the information might be outdated.  Psyros is about to receive a new Europe-wide patent. I see this patent as quite significant; in general, the European Patent Office is very strict and demanding, and the patent description regarding the use of two different wavelengths sounds like something that is at the core of the entire technology’s physical operating mechanism. The fact that this “physical level” patent has moved forward is a pretty direct indication that Psyros’s technology is indeed unique. Based on the patent application, Psyros’s technology is starting to become clearer to me as well. I have long wondered what ultimately makes Psyros so different if it ultimately uses bioluminescence. Well, now it’s starting to make sense: In Psyros’s case, the use of these two lights is based on precise control of the reaction. The first light excites correctly bound reagent molecules into a special, temporary, and sensitive “excited state.” It’s about creating an extremely specific event and eliminating all possible false signals. This acts as a specificity filter. Next, a second light—to which only the correctly bound and activated reagent molecules react—triggers a permanent photochemical reaction, creating a measurable spot on the substrate, and this serves as a second specificity filter. So now Prolight is getting a patent specifically for creating such a step-by-step process using light. This generally makes bypassing the patent very difficult. Additionally, I learned that Psyros’s previous patents from another patent family (* WO2022123000A1 or EP4012423A1) protect these specific chemicals. Not just the specific molecules Psyros uses, but also similar molecular structures that function in the same way—specifically combination molecules where a photoactive reporter molecule is conjugated to an antibody or other sensor molecule. In other words, in addition to the technology, Prolight has developed its own chemical processes, and competitors would have to invent a very new or different molecular structure to produce reagents that function the same way. Furthermore, Prolight’s patent family includes the manufacturing method for these molecules, test kits, the technology itself (optics and measurement devices), and the measurement process. If this is the best-performing technology for measuring biomarkers, then this is quite a comprehensive and valuable stack of patents. And the patents effectively prevent third-party manufacturers from making test kits for Prolight’s devices. It’s starting to look like the devices will be sold very cheaply, and the profit will be made through test kits and high volume. Sounds like the printer business model already? The stock market reaction is very moderate, but in light of this new understanding, I’m adding more “lottery tickets” to my portfolio.

Did it eventually reach exactly 100% after all? Can it be possible? With what probability?  I don’t know. I initially interpreted that applications exceeded 100% and it was just capped at 100% according to the terms of the offering, but the wording suggests that exactly the missing amount of subscriptions without subscription rights were received.  In addition, applications have been received to subscribe for 149 686 965 shares without subscription rights, corresponding to approximately 29.8 percent of the Rights Issue.  That makes the situation sound like the subscriptions were almost full and someone who knew the number of available subscriptions decided to subscribe for the remaining shares at the last minute, with the share clearly being higher than the subscription price. If the situation had been a clear oversubscription, the board would probably have already decided to distribute more shares with the authorization given to it by the general meeting, or we will get a press release about it on Monday.

It probably wouldn’t make it to the main list, no. Here is the schedule included in the investor presentation held at the end of last month on 24.6:  Pre-clinical validation studies are marked for H1 2025. Although it seems that St Thomas’ studies will continue for a while longer. Clinical validation is estimated to be 9 months long, and IVDR approval is hoped for in H2 2026. This would seem quite record-fast for a few-month IVDR approval, including the external evaluation of the application. This does raise a few questions. It somewhat suggests that they had to include somewhat optimistic figures to ensure the offering wouldn’t fail. Well, as positive news: the stock has risen a nice 50% from the subscription.

Did it end up being exactly 100% after all? Can it be possible? With what probability?  Unfortunately, I couldn’t make it. There is no visibility into the schedule. It cannot be that the official offering prospectus states that results will be available by the end of June, if in reality it means that 25/120 results will come and the rest will come when ready.  In connection with the offering, it was stated that it would begin in H2 2025:  A positive outcome will be essential to advance toward a strategic partnership and enable completion of the full regulatory clinical performance study, which is expected to begin in the second half of 2025.  I have understood that the previous study must be completed before the next study. So, it remains to be seen if the previous study will even be completed during H2, and if so, will the final study be able to start immediately after it, still within this year? And if it does, will results be obtained before funds run out again in early H2 2026? Overall, from this:  The results from the ongoing whole blood study using patient samples from St. Thomas’ Hospital are expected to be published before the end of Q2 2025 and represent a highly important milestone, as they could confirm the system’s performance on whole blood. Data confirming Psyros performance on whole blood has been requested by both the market and potential strategic partners. A positive outcome will be essential to advance toward a strategic partnership and enable completion of the full regulatory clinical performance study, which is expected to begin in the second half of 2025.  one gets the impression that the St. Thomas study was completed by the end of Q2 and the next study would have been ready to start immediately after, perhaps already during Q3. Such a procedure would probably not pass on the main list.

Did anyone attend the shareholders’ meeting or the investor presentation held at the end of the month? I would be very interested to know what the management said about future schedule targets. I find the company’s communication regarding the schedules rather odd.  Pre-validation results were supposed to come in Q4 2024, and the actual validation was supposed to start in early 2025. Pre-validation results were reported to come in Q1 2025. Pre-validation results came at the end of Q1, but they were partial and very superficial. Whole blood results were reported to be only coming in H1 2025. Whole blood results came on June 16th (image below), but they are also only preliminary, and results are still being collected. The actual validation was supposed to start in early 2025, but the company has not communicated anything about a delay or stated what has been the impediment.   The same stock exchange release implies that this is the “first phase of the study,” which leaves it unclear whether new phases are occurring before the final clinical study.  Successful completion of the first phase of this study marks another milestone as we prepare for our pivotal clinical study.

Prolight Diagnostics

Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026...

<div class="mfn-body"><p>Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026, Prolight is firmly setting its sights on a commercial launch in 2027.&nbsp;</p><p>Read the full article here: <a rel="noopener" href="https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/">https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/</a></p></div><div class="mfn-footer mfn-contacts mfn-de1edede6694"><p><strong class="mfn-heading-1">For further information, please contact:</strong><br>Ulf Bladin, CEO<br>E-mail: <a rel="noopener" href="mailto:info@prolightdx.com">info@prolightdx.com</a><br>Phone: +46 73 582 39 87<br>Company website: <a rel="noopener" href="http://www.prolightdx.com">www.prolightdx.com</a></p></div><div class="mfn-footer mfn-about mfn-59c4de0219f5"><p><strong class="mfn-heading-1">About Us</strong><br>Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.<br>&nbsp;<br>The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/c2c78220-9fcf-42ad-9323-83b68e1342f6/biostock-publishes-an-article-after-prolight-published-its-year-end-report-for-2025.pdf" class="mfn-generated mfn-primary">Biostock publishes an article after Prolight published its Year-End Report for 2025</a></p></div>